NYSE •
Healthcare •
Drug Manufacturers - General •
Quote as of 05/29/2026
Company Profile
IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeNYSE
Market Capitalization202,265 mln
Float3,186 mln
Earnings Date08/05/2026
EPS
4.27
Solid
P / E
10.67
Fair value
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-2.56
Likely reliable
1-Year Forecast
46.88
Fairly priced
Relative Strength
29
/ 100
Underperforming
Business Description
Founded in Denmark in 1923, Novo Nordisk is a global pharmaceutical company best known for its treatments targeting diabetes and obesity, as well as medicines for patients living with rare blood and hormonal conditions. The company sells its products across more than 50 countries, supported by a broad portfolio that includes smart insulin delivery devices and digital dosing tools. With over a century of experience, Novo Nordisk remains one of the most recognized names in metabolic and rare disease medicine worldwide.
